Treatment of chronic post-radiation cystitis with trans-urethral amniotic bladder therapy appears durable at 9 months: A clinical study.
Jonathan LutchkaJack VercnockeEmily FisherCodrut RadoiuJulian JeberaeelSteven LucasNivedita DharPublished in: Urologia (2024)
Our data suggest that a significant number of CRC patients may have durable benefit after ABT. Despite this, some of them can show symptoms rebound at 24 weeks.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- spinal cord injury
- prognostic factors
- peritoneal dialysis
- clinical trial
- stem cells
- physical activity
- big data
- patient reported outcomes
- machine learning
- depressive symptoms
- replacement therapy
- urinary tract
- preterm birth
- artificial intelligence
- smoking cessation